The Limited Times

Now you can see non-English news...

Biontech: Corona vaccine manufacturer makes a profit of 10.3 billion euros

2022-03-30T12:36:02.553Z


Biontech: Corona vaccine manufacturer makes a profit of 10.3 billion euros Created: 03/30/2022, 14:27 The corona vaccine manufacturer Biontech was able to increase sales and profits enormously last year. © Rob Welham/Imago Images The corona vaccine manufacturer Biontech was able to increase its sales enormously compared to 2020. The net profit of the Mainz company is around 10.3 billion euros.


Biontech: Corona vaccine manufacturer makes a profit of 10.3 billion euros

Created: 03/30/2022, 14:27

The corona vaccine manufacturer Biontech was able to increase sales and profits enormously last year.

© Rob Welham/Imago Images

The corona vaccine manufacturer Biontech was able to increase its sales enormously compared to 2020.

The net profit of the Mainz company is around 10.3 billion euros.

Mainz – The Corona* vaccine manufacturer Biontech made a net profit of around 10.3 billion euros last year.

Sales were almost 19 billion euros, as the Mainz-based company announced on Wednesday.

In terms of both net profit and sales, Biontech was significantly higher than the figures for 2020, which were 15.2 million euros and 482 million euros respectively.

Biontech has now confirmed the sales forecast for its Covid 19 vaccine * of 13 billion to 17 billion euros this year.

Biontech: Study on Omicron vaccine should support approval

According to the company, it expects to publish the first data from the clinical study on the safety, tolerability and effectiveness of a vaccine tailored to the omicron variant in April, which should support possible applications for approval.

Around 2150 adults are taking part in the study.

The current Covid-19 vaccine and an omicron-based vaccine are being investigated in both test persons who have already been vaccinated and those who have not been vaccinated so far.

According to Biontech, the study was expanded to include various combination approaches.

Other vaccine candidates are also to be tested.

Biontech: Management wants share buyback program

Management intends to approve a share buyback program of up to $1.5 billion over the next two years and propose a special dividend of $2 per share.

Last year, 2.6 billion corona vaccine doses were delivered, 100 million more than expected.

Research and development spending is expected to increase by around 50 percent this year compared to 2021, to between EUR 1.4 billion and EUR 1.5 billion.

(dpa) *Merkur.de is an offer from IPPEN.MEDIA.

Source: merkur

All news articles on 2022-03-30

You may like

News/Politics 2024-03-18T14:18:09.201Z
News/Politics 2024-03-16T18:46:42.470Z

Trends 24h

News/Politics 2024-03-28T06:04:53.137Z

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.